Message from the CEO
IBT reached several significant milestones during 2018. IBT reached agreement with a CRO (Contract Research Organization) to conduct the pivotal Phase III clinical trial, The Connection Study, and the listing change of IBT´s class B shares to Nasdaq Stockholm was completed.
As previously communicated, IBT had a meeting with the Food and Drug Administration (FDA) on November 20, 2018, to discuss IBT’s protocol, which in detail describes IBT’s clinical development program. The meeting was fruitful and, among other things, IBT received guidance from the FDA regarding possible improvements to the protocol. During the meeting there was discussion of the fact that the primary endpoint of the study solely included observations regarding NEC, in spite of the fact that our pharmaceutical candidate IBP-9414 also has the possibility to show other clinical effects which may help premature infants, for example so-called “feeding intolerance”. Since the meeting with the FDA we have been working to include parameters related to feeding intolerance in our clinical program. Consequently, we plan a combined primary endpoint in which both NEC and feeding intolerance are included, which in practice means that we give the study a further chance for success.
In parallel with revision of the protocol, IBT has made other preparations for the start of The Connection Study, including progress in contracting hospitals, manufacturing of clinical trial material and strengthening the organization. Finally, it is worth mentioning that we continue our contacts with potential marketing and distribution partners.
We maintain our plan to dose the first patient in The Connection Study during the first half of this year.
Stockholm February 8, 2019
Chief Executive Officer
|Selected financial data|
|000's||2018 Oct-Dec||2017 Oct-Dec||2018 Jan-Dec||2017 Jan-Dec|
|Operating profit/loss||-23 837||-9 060||-39 417||-36 141|
|Result after tax, SEK||-24 143||-9 060||-40 607||-36 156|
|Total assets||563 371||175 024||563 371||175 024|
|Cash flow for the period (SEK)||-27 322||91 098||381 544||64 488|
|Cash flow per share for the period (SEK)||-2.43||15.52||35.36||11.53|
|Cash||542 170||158 274||542 170||158 274|
|Earnings per share before and after dilution (SEK)||-2.15||-1.44||-3.76||-6.05|
|Equity per share (SEK)||49.59||11.97||49.59||25.50|
|Equity ratio (%)||99%||96%||99%||96%|
* Operational costs for the fourth quarter include exchange rate gains on forward currency contracts and currency deposits amounting to 1 442 (0) KSEK. Operational costs amounted to 25 279 (9 060) KSEK prior to exchange rate gains. Operational costs for the nine- month period include exchange rate gains on forward currency contracts and forward currency deposits amounting to 12 009 (0) KSEK. Operational costs amounted to 51 426 (36 379) KSEK prior to exchange rate gains (Note 2)
Significant events during the fourth quarter (Oct-Dec) 2018
Significant events during the reporting period (Jan-Dec) 2018
Significant events after the reporting period
About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) (“IBT”) is a clinical stage pharmaceutical company with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.
IBT is developing drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC), a devastating and often fatal disease in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT has an additional project in its portfolio, a second rare disease program, IBP-1016, for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.
Infant Bacterial Therapeutics (IBT B) shares are listed on Nasdaq Stockholm.